We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Regulatory T-cell Responsiveness Predicts Risk of Cancer Relapse

By LabMedica International staff writers
Posted on 15 Jul 2019
The risk of future breast cancer relapse can be predicted by analyzing the signaling responsiveness of peripheral blood Treg II cells (CD45RA−FOXP3hi Treg cells) to immunosuppressive T helper type 1 (TH1) and T helper type 2 (TH2) cytokines.

Th1 helper cells lead to an increased cell-mediated response, typically against intracellular bacteria and protozoa. More...
Th2 helper cells lead to a humoral immune response, typically against extracellular parasites including helminths.

The regulatory T-cells (Tregs) are a subpopulation of T-cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Tregs are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T-cells. Tregs express the biomarkers CD4, FOXP3, and CD25 and are thought to be derived from the same lineage as naïve CD4 cells. Because effector T-cells also express CD4 and CD25, Tregs are very hard to effectively discern from effector CD4+, making them difficult to study.

Investigators at City of Hope (Duarte, CA, USA) studied the origin of breast cancer- related intratumoral Treg cells and their relationship with peripheral blood Treg cells. In this study, the investigators evaluated data on 40 breast cancer patients who had been monitored for a median of four years. Results were validated in a separate cohort of 38 additional breast cancer patients to create a benchmark that could be used to predict whether a breast cancer patient would be likely to relapse within a short span of years.

“This is the first success linking a solid tumor with blood biomarkers - an indicator of whether a patient will remain in remission,” said senior author Dr. Peter P. Lee, professor of cancer immunotherapeutics at City of Hope. “When patients are first diagnosed with cancer, it is important to identify those at higher risk for relapse for more aggressive treatments and monitoring. Staging and new tests based on genomics analysis of the tumor are currently available for risk stratification. However, a predictive blood test would be even more attractive but is not yet available. We are trying to change the status quo. Knowing the chance of cancer relapse will inform doctors how aggressive a particular patient’s cancer treatment should be.”

The breast cancer relapse study was published in the July 8, 2019, online edition of the journal Nature Immunology.

Related Links:
City of Hope


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.